Spectrum is a commercial stage biopharmaceutical company, with a strategy of acquiring, developing, and commercializing novel and targeted oncology therapies. The company has an in-house clinical development organization with regulatory and data management capabilities, in addition to commercial infrastructure and a field based sales force for Spectrum's marketed product, ROLVEDON™ (eflapegrastim-xnst) Injection.